Barclays PLC Eye Point Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 245,045 shares of EYPT stock, worth $1.74 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

245,045

Previous 245,045 -0.0%

Holding current value

$1.74 Million

Previous $1.96 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$7.58 - $10.54 $1.49 Million - $2.08 Million	197,033 Added 410.38%	245,045 $1.96 Million
Q2 2024 Aug 14, 2024	SELL	$8.16 - $22.89 $960,228 - $2.69 Million	-117,675 Reduced 71.02%	48,012 $418,000
Q1 2024 May 15, 2024	BUY	$19.93 - $29.71 $120,476 - $179,596	6,045 Added 3.79%	165,687 $3.43 Million
Q4 2023 Feb 15, 2024	BUY	$5.71 - $24.13 $650,842 - $2.75 Million	113,983 Added 249.64%	159,642 $3.69 Million
Q3 2023 Nov 07, 2023	BUY	$7.99 - $15.36 $185,431 - $356,474	23,208 Added 103.37%	45,659 $365,000
Q2 2023 Aug 03, 2023	SELL	$3.03 - $9.0 $16,734 - $49,707	-5,523 Reduced 19.74%	22,451 $195,000
Q1 2023 May 04, 2023	BUY	$2.28 - $5.04 $47,809 - $105,683	20,969 Added 299.34%	27,974 $82,000
Q4 2022 Feb 13, 2023	BUY	$2.37 - $7.2 $13,980 - $42,472	5,899 Added 533.36%	7,005 $25,000
Q3 2022 Nov 03, 2022	SELL	$6.96 - $11.12 $1,412 - $2,257	-203 Reduced 15.51%	1,106 $9,000
Q2 2022 Aug 12, 2022	SELL	$7.25 - $12.71 $19,843 - $34,787	-2,737 Reduced 67.65%	1,309 $10,000
Q1 2022 May 16, 2022	BUY	$8.67 - $14.11 $35,078 - $57,089	4,046 New	4,046 $49,000

Others Institutions Holding EYPT

# of Institutions

150

Shares Held

58M

Call Options Held

177K

Put Options Held

263K

View Full List

About EyePoint Pharmaceuticals, Inc.

Ticker EYPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,072,200
Market Cap $242M
Description
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...

More about EYPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account